Kaygusuz-Atagunduz Isik, Toptas Tayfur, Yumuk Fulden, Firatli-Tuglular Tulin, Bayik Mahmut
Department of Internal Medicine, Divisions of Hematology, Marmara University Hospital, Istanbul, Turkey.
J Cancer Res Ther. 2014 Oct-Dec;10(4):1107-8. doi: 10.4103/0973-1482.146095.
Imatinib mesylate is the standard treatment of chronic myeloid leukemia (CML). Despite imatinib is being used in the treatment of other malignancies as well, its potential role on de novo tumor growth is not known. Secondary malignancies are rarely seen in patients with CML and particularly in those receiving imatinib. Here, we present a CML patient taking imatinib therapy that was diagnosed to have breast cancer and received adjuvant chemo-and radiotherapy with imatinib. We tried to explain co-occurrence of these rare events by probable pathogenetic mechanisms.
甲磺酸伊马替尼是慢性粒细胞白血病(CML)的标准治疗药物。尽管甲磺酸伊马替尼也被用于治疗其他恶性肿瘤,但其对肿瘤新生的潜在作用尚不清楚。继发性恶性肿瘤在CML患者中很少见,尤其是在接受甲磺酸伊马替尼治疗的患者中。在此,我们报告1例接受甲磺酸伊马替尼治疗的CML患者,该患者被诊断患有乳腺癌,并在服用甲磺酸伊马替尼的同时接受了辅助化疗和放疗。我们试图通过可能的发病机制来解释这些罕见事件的同时发生。